Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of a CHO cell recombinant zoster vaccine in adults aged 40 years and older
CTR20252173Phase 2Active
- Sponsor
- Genevax
- Start
- Jun 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Zoster vaccine recombinant in herpes zoster (HZ), sponsored by Genevax. Started Jun 2025; status: active.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on CTR20252173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252173.